Cargando…

Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?

A triad of high triglycerides, low high-density lipoprotein (HDL) cholesterol, and elevated small dense low-density lipoprotein particles occurring in a patient with type 2 diabetes is referred to atherogenic diabetic dyslipidemia (ADD). Despite statin therapy, a significant residual risk remains po...

Descripción completa

Detalles Bibliográficos
Autores principales: Munigoti, Srinivasa P., Harinarayan, C. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056123/
https://www.ncbi.nlm.nih.gov/pubmed/24944919
http://dx.doi.org/10.4103/2230-8210.131134
_version_ 1782320789318533120
author Munigoti, Srinivasa P.
Harinarayan, C. V.
author_facet Munigoti, Srinivasa P.
Harinarayan, C. V.
author_sort Munigoti, Srinivasa P.
collection PubMed
description A triad of high triglycerides, low high-density lipoprotein (HDL) cholesterol, and elevated small dense low-density lipoprotein particles occurring in a patient with type 2 diabetes is referred to atherogenic diabetic dyslipidemia (ADD). Despite statin therapy, a significant residual risk remains potentially attributable to increased triglyceride concentration and low HDL cholesterol, a characteristic hallmark of ADD. Current therapeutic options in reducing this residual risk include nicotinic acid, omega 3 fatty acids, and selective peroxisome proliferator-activated receptor-alpha (PPAR) agonists (fibrates). These drugs are limited in their potential either by lack of evidence to support their role in reducing cardiovascular events or due to their side effects. This review details their current status and also the role of new glitazar, saroglitazar adual PPARα/γ agonist with predominant PPARα activity in the management of ADD.
format Online
Article
Text
id pubmed-4056123
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-40561232014-06-18 Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone? Munigoti, Srinivasa P. Harinarayan, C. V. Indian J Endocrinol Metab Review Article A triad of high triglycerides, low high-density lipoprotein (HDL) cholesterol, and elevated small dense low-density lipoprotein particles occurring in a patient with type 2 diabetes is referred to atherogenic diabetic dyslipidemia (ADD). Despite statin therapy, a significant residual risk remains potentially attributable to increased triglyceride concentration and low HDL cholesterol, a characteristic hallmark of ADD. Current therapeutic options in reducing this residual risk include nicotinic acid, omega 3 fatty acids, and selective peroxisome proliferator-activated receptor-alpha (PPAR) agonists (fibrates). These drugs are limited in their potential either by lack of evidence to support their role in reducing cardiovascular events or due to their side effects. This review details their current status and also the role of new glitazar, saroglitazar adual PPARα/γ agonist with predominant PPARα activity in the management of ADD. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4056123/ /pubmed/24944919 http://dx.doi.org/10.4103/2230-8210.131134 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Munigoti, Srinivasa P.
Harinarayan, C. V.
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
title Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
title_full Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
title_fullStr Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
title_full_unstemmed Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
title_short Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
title_sort role of glitazars in atherogenic dyslipidemia and diabetes: two birds with one stone?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056123/
https://www.ncbi.nlm.nih.gov/pubmed/24944919
http://dx.doi.org/10.4103/2230-8210.131134
work_keys_str_mv AT munigotisrinivasap roleofglitazarsinatherogenicdyslipidemiaanddiabetestwobirdswithonestone
AT harinarayancv roleofglitazarsinatherogenicdyslipidemiaanddiabetestwobirdswithonestone